Lexicon Pharmaceutical ( Lexicon Pharmaceutical )

Lexicon Pharmaceutical

Lexicon Pharmaceutical's picture

About Lexicon Pharmaceutical

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing breakthrough treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Arthur T Sands, Ray B Webb and. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets.

Lexicon Pharmaceutical press release, blog etc

10/16/2018 - 08:38 Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of Xermelo (telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
09/24/2018 - 06:42 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 54th Annual Meeting
06/23/2018 - 21:07 Lexicon Pharmaceuticals Announces Positive 52-week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care
06/22/2018 - 21:13 Lexicon Pharmaceuticals Announces Positive 52-week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
06/18/2018 - 17:11 Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions
05/22/2018 - 08:14 FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
05/04/2018 - 04:20 Lexicon Pharmaceuticals Announces Publication of New Xermelo (telotristat Ethyl) Data in Clinical Therapeutics
03/28/2018 - 23:37 Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults with Type 1 Diabetes
03/26/2018 - 04:55 Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes
02/28/2018 - 05:56 Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
01/02/2018 - 15:44 Lexicon Pharmaceuticals Announces Poster Presentation at ASCO GI
01/02/2018 - 06:59 Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
12/05/2017 - 17:15 Lexicon Pharmaceuticals Secures Up To $200 Million Non-dilutive Term Loan Financing
09/27/2017 - 04:24 Lexicon Pharmaceuticals Initiates Patient Dosing in a Phase 1 Study of LX9211
09/19/2017 - 14:19 European Commission Approves Xermelo (Telotristat ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
09/18/2017 - 06:05 Lexicon Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
09/13/2017 - 04:10 New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes
09/08/2017 - 09:02 Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data from Pivotal Phase 3 Intandem1 and inTandem2 Studies of Sotagliflozin